PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

Table 3

Pretreatment and posttreatment clinical characteristics of type 2 diabetes patients with hypertriglyceridemia treated with fenofibrate.

Parameters	Pretreatment; ()	Posttreatment; ()	P value
BMI (kg/m^2)	26.46 ± 4.60	26.37 ± 4.59	0.209
SBP (mmHg)	125.00 ± 7.56	125.48 ± 6.76	0.668
DBP (mmHg)	74.24 ± 8.74	73.92 ± 7.30	0.831
FBG (mmol/L)	7.42 ± 1.01	7.32 ± 1.00	0.215
TC (mmol/L)	4.62 ± 0.66	4.83 ± 0.69	0.145
HDL (mmol/L)	1.25 ± 0.29	1.47 ± 0.27	<0.001
LDL (mmol/L)	2.80 ± 0.53	2.82 ± 0.66	0.845
TG (mmol/L)	3.05 ± 0.86	1.84 ± 0.76	<0.001
AST (U/L)	22.08 ± 7.33	23.84 ± 9.04	0.322
ALT (U/L)	26.00 ± 5.69	24.44 ± 11.64	0.518
CR (μmol/L)	71.92 ± 13.74	76.10 ± 17.29	0.164
CK (U/L)	84.64 ± 27.69	91.20 ± 37.28	0.307

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CR, creatinine; CK, creatine kinase.